middle.news
Anteris builds DurAVR capacity as pivotal trial expands into new markets
9:12am on Wednesday 11th of November, 2026 AEDT
•
Healthcare
Read Story
Anteris builds DurAVR capacity as pivotal trial expands into new markets
9:12am on Wednesday 11th of November, 2026 AEDT
Key Points
US$26.8 million third-quarter net loss, up 21% year on year
R&D expense rose 27% to US$21.3 million
US$22.9 million operating cash outflow during the quarter
PARADIGM trial expanded across North America and Europe, with Germany and Australia added after quarter-end
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE